MedPath

Management of Blood Pressure by Trivrit and Aragvadha Churna as daily mild laxative

Phase 4
Not yet recruiting
Conditions
Essential (primary) hypertension,
Registration Number
CTRI/2019/11/022040
Lead Sponsor
Dr Manju Mohan
Brief Summary

Patients will be recruited from inclusion criteria and study the effect of  Trivrit and Aragvadha Churna Nitya virechana in Stage 1 Essential Hypertension

To study the effect of Nitya virechana with Trivrit Churna on systolic and diastolic blood pressure.

To study the effect of Nitya virechana with Aragvadha Churna on systolic and diastolic blood pressure

To compare the effect of Nitya virechana with Trivrit and Aragvadha churna on systolic and diastolic blood pressure.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria
  • 1.Patients of either sex between the age group of 30-60 yrs will be selected.
  • 2.Newly detected cases of Stage 1 Essential Hypertension will be selected.
Exclusion Criteria

1.Hypertension associated with: a.Cardio-vascular diseases b.Cerebro-vascular diseases c.Hypothyroidism d.Diabetes Mellitus (Type 1/ Type 2/ GDM) e.Pregnant and lactating women.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Reduce in the symptoms and range of Blood pressureSix months
Secondary Outcome Measures
NameTimeMethod
1.To study the effect of Nitya Virechana with Trivrit Churna on Systolic and Diastolic blood pressure.2.To study the effect of Nitya Virechana with Aragvadha Churna on Systolic and Diastolic blood pressure.

Trial Locations

Locations (1)

Mahatma Gandhi Ayurved College Hospital and Research Center Salod (H) Wardha

🇮🇳

Wardha, MAHARASHTRA, India

Mahatma Gandhi Ayurved College Hospital and Research Center Salod (H) Wardha
🇮🇳Wardha, MAHARASHTRA, India
Dr Manju Mohan
Principal investigator
manjumohan13@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.